Results for this period
First quarter1 January 2026–31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Sales increased, driven mainly by direct sales, with new urology products performing particularly well. However, profit declined because the weaker yen raised the cost-of-sales ratio and costs for developing new overseas markets also increased.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–31 March 2026 |
| Net Sales | ¥3,364 million (YoY +4.5%) |
| Operating profit | ¥140 million (YoY -36.6%) |
| Ordinary income | ¥169 million (YoY -21.3%) |
| Profit attributable to owners of the parent | ¥153 million (YoY -26.7%) |
| Net income per share | 18.40 |
| Equity ratio | End of the current fiscal period 81.6 / End of previous period 81.1 |
| Total assets | ¥19,918 million |
| Net assets | ¥16,260 million |
| Full-year earnings forecast | Net Sales ¥13,960 million (YoY +2.5%) / Operating profit ¥1,060 million (YoY +5.5%) / Ordinary income ¥1,070 million (YoY +8.3%) / Net income ¥750 million (YoY +5.1%) |
| Annual Dividend Forecast | ¥45 → ¥47 |
| Depreciation and amortization | ¥151,906 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Subsidy Income ¥923 thousand / Extraordinary loss Not disclosed |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | No (0 additions, 0 exclusions) |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 9,664,327 |
| Treasury Shares at Period-End | 1,490,420 |
| Factors Behind Changes in Business Performance | Sales increased, driven mainly by direct sales, with new urology products performing particularly well. However, profit declined because the weaker yen raised the cost-of-sales ratio and costs for developing new overseas markets also increased. |
Items this document does not state (14)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Sales increased, driven mainly by direct sales, with new urology products performing particularly well. However, operating income, ordinary income and net income attributable to owners of the parent declined because the weaker yen increased the cost-of-sales ratio and costs for developing new overseas markets also rose.